Shareholders in Collins Foods (ASX:CKF) are in the red if they invested three years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But if you try your hand at stock picking, you risk returning less than the market. Unfortunately, that's been the case for longer term Collins Foods Limited (ASX:CKF) shareholders, since the share price is down 16% in the last three years, falling well short of the market return of around 25%.
So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.
We check all companies for important risks. See what we found for Collins Foods in our free report.
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
During the unfortunate three years of share price decline, Collins Foods actually saw its earnings per share (EPS) improve by 5.3% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Alternatively, growth expectations may have been unreasonable in the past.
Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.
We note that, in three years, revenue has actually grown at a 10% annual rate, so that doesn't seem to be a reason to sell shares. It's probably worth investigating Collins Foods further; while we may be missing something on this analysis, there might also be an opportunity.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. If you are thinking of buying or selling Collins Foods stock, you should check out this free report showing analyst profit forecasts.
It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, Collins Foods' TSR for the last 3 years was -7.8%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!
Collins Foods shareholders are down 9.3% for the year (even including dividends), but the market itself is up 8.6%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 4% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Trigg Minerals Loses AU$10.0m Market Value But Insiders See Windfall Of AU$6.0m
Insiders who purchased Trigg Minerals Limited (ASX:TMG) shares in the past 12 months are unlikely to be deeply impacted by the stock's 12% decline over the past week. Even after accounting for the recent loss, the AU$700.1k worth of stock purchased by them is now worth AU$6.68m or in other words, their investment continues to give good returns. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Over the last year, we can see that the biggest insider purchase was by insider Yonglu Yu for AU$357k worth of shares, at about AU$0.007 per share. We do like to see buying, but this purchase was made at well below the current price of AU$0.082. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices. Over the last year, we can see that insiders have bought 81.51m shares worth AU$700k. But insiders sold 1.00m shares worth AU$11k. In the last twelve months there was more buying than selling by Trigg Minerals insiders. The average buy price was around AU$0.0086. To my mind it is good that insiders have invested their own money in the company. However, we do note that they were buying at significantly lower prices than today's share price. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! See our latest analysis for Trigg Minerals There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them). Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Insiders own 21% of Trigg Minerals shares, worth about AU$16m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. Insiders own shares in Trigg Minerals and we see no evidence to suggest they are worried about the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example, Trigg Minerals has 5 warning signs (and 3 which are significant) we think you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Insiders are the top stockholders in Regis Healthcare Limited (ASX:REG), and the recent 6.9% drop might have disappointed them
Regis Healthcare's significant insider ownership suggests inherent interests in company's expansion A total of 4 investors have a majority stake in the company with 52% ownership Institutional ownership in Regis Healthcare is 17% AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Every investor in Regis Healthcare Limited (ASX:REG) should be aware of the most powerful shareholder groups. With 45% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). As market cap fell to AU$2.2b last week, insiders would have faced the highest losses than any other shareholder groups of the company. Let's take a closer look to see what the different types of shareholders can tell us about Regis Healthcare. View our latest analysis for Regis Healthcare Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in Regis Healthcare. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Regis Healthcare, (below). Of course, keep in mind that there are other factors to consider, too. We note that hedge funds don't have a meaningful investment in Regis Healthcare. Looking at our data, we can see that the largest shareholder is Ian Roberts with 27% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 16% and 4.9%, of the shares outstanding, respectively. On looking further, we found that 52% of the shares are owned by the top 4 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. It seems insiders own a significant proportion of Regis Healthcare Limited. It is very interesting to see that insiders have a meaningful AU$999m stake in this AU$2.2b business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently. The general public, who are usually individual investors, hold a 37% stake in Regis Healthcare. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Regis Healthcare is showing 1 warning sign in our investment analysis , you should know about... If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
5 hours ago
- Yahoo
ASX Value Stock Picks Including Lynas Rare Earths For Estimated Growth
As the ASX200 flirts with record highs, investor sentiment in Australia is cautiously optimistic, buoyed by potential trade deals and corporate activities like mergers and acquisitions. In such a climate, identifying undervalued stocks becomes crucial for investors looking to capitalize on market opportunities; companies with strong fundamentals and growth potential can offer promising prospects even amidst fluctuating sector performances. Name Current Price Fair Value (Est) Discount (Est) Superloop (ASX:SLC) A$2.85 A$4.92 42.1% Ridley (ASX:RIC) A$2.86 A$5.64 49.3% Praemium (ASX:PPS) A$0.685 A$1.16 40.8% Polymetals Resources (ASX:POL) A$0.825 A$1.54 46.3% PointsBet Holdings (ASX:PBH) A$1.195 A$2.05 41.8% Nuix (ASX:NXL) A$2.35 A$4.04 41.8% Nanosonics (ASX:NAN) A$4.35 A$6.92 37.1% Fenix Resources (ASX:FEX) A$0.285 A$0.47 38.9% Charter Hall Group (ASX:CHC) A$19.35 A$33.88 42.9% Capricorn Metals (ASX:CMM) A$9.12 A$14.62 37.6% Click here to see the full list of 32 stocks from our Undervalued ASX Stocks Based On Cash Flows screener. Underneath we present a selection of stocks filtered out by our screen. Overview: Lynas Rare Earths Limited operates in the exploration, development, mining, extraction, and processing of rare earth minerals in Australia and Malaysia with a market capitalization of A$8.04 billion. Operations: The company generates revenue primarily from its rare earth operations, amounting to A$482.82 million. Estimated Discount To Fair Value: 36.5% Lynas Rare Earths is trading at A$8.6, significantly below its estimated fair value of A$13.55, suggesting it may be undervalued based on discounted cash flow analysis. Despite a decline in profit margins from 33.2% to 10.5%, the company is expected to experience substantial earnings growth of over 61% annually, with revenue projected to grow at 38% per year, outpacing the broader Australian market's growth expectations. Our growth report here indicates Lynas Rare Earths may be poised for an improving outlook. Unlock comprehensive insights into our analysis of Lynas Rare Earths stock in this financial health report. Overview: Nanosonics Limited is a global infection prevention company with a market cap of A$1.32 billion. Operations: The company's revenue is primarily derived from its Healthcare Equipment segment, totaling A$183.97 million. Estimated Discount To Fair Value: 37.1% Nanosonics, trading at A$4.35, is valued below its estimated fair value of A$6.92, highlighting potential undervaluation based on discounted cash flow analysis. Earnings have grown 14.3% annually over the past five years and are forecast to increase significantly by 24.3% per year, outpacing the Australian market's growth rate of 11.6%. However, its future return on equity is projected to be relatively low at 13.9% in three years' time. The growth report we've compiled suggests that Nanosonics' future prospects could be on the up. Get an in-depth perspective on Nanosonics' balance sheet by reading our health report here. Overview: Ridley Corporation Limited, with a market cap of A$1.05 billion, provides animal nutrition solutions in Australia through its subsidiaries. Operations: The company's revenue is derived from two main segments: Bulk Stockfeeds, contributing A$894.26 million, and Packaged/Ingredients, accounting for A$389.70 million. Estimated Discount To Fair Value: 49.3% Ridley, trading at A$2.86, is priced below its estimated fair value of A$5.64, indicating potential undervaluation based on discounted cash flow analysis. Recent equity and fixed-income offerings might impact shareholder value in the short term. While revenue is expected to grow robustly at 20.7% annually, earnings growth of 16.6% per year surpasses the Australian market average but remains moderate compared to significant benchmarks. The company's dividend history is unstable, and return on equity forecasts are modest at 14.4%. Our expertly prepared growth report on Ridley implies its future financial outlook may be stronger than recent results. Click to explore a detailed breakdown of our findings in Ridley's balance sheet health report. Navigate through the entire inventory of 32 Undervalued ASX Stocks Based On Cash Flows here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:LYC ASX:NAN and ASX:RIC. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
